https://www.selleckchem.com/pr....oducts/mk-5108-vx-68
rly - 15.6%, late - in 21.1%. The least frequent relapses were observed in patients who underwent modified FiLaC technology (Group 2) 6.7% - early relapses and 11.1% - late relapses. The use of the modified FiLaC technology in the treatment of trans- and extrasphincteric fistulas of the rectum made it possible to minimize postoperative complications, fully preserve the function of anal holding, and achieve healing of fistulas in 82.5% of cases with a median follow-up of 31 months. The use of the modified FiLaC technology in the t
Like
Comment
Share
